Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5695386 | Gynecologic Oncology | 2017 | 8 Pages |
Abstract
L1CAM expression could serve as a biomarker for predicting clinical outcome and response to therapy in patients with endometrioid ovarian carcinoma, but not in clear cell carcinomas. L1CAM positivity also predicts poor outcome in patients with concurrent endometrioid ovarian and endometrial carcinomas.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Piret Soovares, Annukka Pasanen, Ralf Bützow, Heini Lassus,